Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH

Dual modulation of FXR and HSD17B13 presents a promising strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). Compound 6, a groundbreaking dual modulator of FXR and HSD17B13, validates the concept of significantly enhancing liver function, reducing inflammation and fibrosis across various MAFLD models.